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Abstract
Background: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common
complication of ERCP and may run a severe course. Evidence suggests that vigorous periprocedural hydration can
prevent PEP, but studies to date have significant methodological drawbacks. Importantly, evidence for its added
value in patients already receiving prophylactic rectal non-steroidal anti-inflammatory drugs (NSAIDs) is lacking and
the cost-effectiveness of the approach has not been investigated. We hypothesize that combination therapy of
rectal NSAIDs and periprocedural hydration would significantly lower the incidence of post-ERCP pancreatitis
compared to rectal NSAIDs alone in moderate- to high-risk patients undergoing ERCP.
Methods: The FLUYT trial is a multicenter, parallel group, open label, superiority randomized controlled trial. A total
of 826 moderate- to high-risk patients undergoing ERCP that receive prophylactic rectal NSAIDs will be randomized
to a control group (no fluids or normal saline with a maximum of 1.5 mL/kg/h and 3 L/24 h) or intervention group
(lactated Ringer’s solution with 20 mL/kg over 60 min at start of ERCP, followed by 3 mL/kg/h for 8 h thereafter).
The primary endpoint is the incidence of post-ERCP pancreatitis. Secondary endpoints include PEP severity,
hydration-related complications, and cost-effectiveness.
Discussion: The FLUYT trial design, including hydration schedule, fluid type, and sample size, maximize its power of
identifying a potential difference in post-ERCP pancreatitis incidence in patients receiving prophylactic rectal NSAIDs.
Trial registration: EudraCT: 2015-000829-37. Registered on 18 February 2015.
ISRCTN: 13659155. Registered on 18 May 2015.
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Background
Endoscopic retrograde cholangiopancreatography (ERCP)
is widely used to treat diseases of the pancreaticobiliary
tree. The most frequent complication is post-ERCP pan-
creatitis (PEP) [1]. The reported overall incidence varies
from 7% to 10% and approaches 15% in high-risk patients
[2]. In the United States, costs related to PEP are esti-
mated to be over $200 million annually [3].
Numerous prophylactic measures for PEP have been in-
vestigated [4]. However, the evidence is indisputable for
only two measures – rectal non-steroidal anti-inflammatory
drugs (NSAIDs) and prophylactic pancreatic duct (PD)
stents. Recent meta-analyses calculated an odds ratio
of 0.44 for rectal NSAIDs [5] and 0.35 for PD stents [6].
Therefore, the American Society for Gastrointestinal
Endoscopy recommends the use of rectal NSAIDs and PD
stents in high-risk patients and suggests the use of rectal
NSAIDs in average-risk patients [7]. The European Society
for Gastrointestinal Endoscopy (ESGE) recommends rou-
tine use of rectal NSAIDs in all patients undergoing ERCP,
while reserving PD stents for high-risk patients [4].
A new promising prophylactic strategy for PEP is peri-
procedural hydration. It is intended to preserve adequate
pancreatic perfusion and tissue oxygenation during
ERCP. The strategy finds its justification in the theory
that early pancreatic microcirculatory perfusion derange-
ments are correlated with severity of acute pancreatitis
[8]. Circumstantial evidence supporting this theory is
that an increased level of pre-procedural blood urea
nitrogen, a marker of hemoconcentration, has been
associated with PEP development and severity [9, 10].
Many patients subjected to ERCP are fasting and may
therefore be relatively dehydrated. Furthermore, a retro-
spective cohort study found an inverse relationship
between peri-ERCP hydration and PEP severity [11].
A recent meta-analysis on periprocedural hydration
[12], including seven RCTs with 1047 patients, showed
an odds ratio of 0.47 (0.30–0.72; P = 0.0006) in favor of
protection against PEP. There was no significant differ-
ence in adverse events between the intervention and
control groups (P = 0.23). However, the included RCTs
had several shortcomings, the most important of which
being that patients did not receive rectal NSAIDs –
these cannot be withheld from patients due to the clear
evidence in favor of their use [13]. Furthermore, a syner-
gistic effect of hydration and rectal NSAIDs is plausible
because both act at a different stage of PEP develop-
ment; hydration preserves pancreatic microcirculation
and NSAIDs suppress the inflammatory response.
The FLUYT trial is designed to investigate whether
periprocedural hydration with lactated Ringer’s solution
can prevent post-ERCP pancreatitis in moderate- to
high-risk patients undergoing ERCP who already receive
prophylactic rectal NSAIDs.
Methods
The trial protocol is written in accordance with the
SPIRIT guidelines (Fig. 1, Additional file 1) [14].
Study setting
The FLUYT trial is a multicenter, parallel group, open
label, superiority randomized controlled trial that will
include 826 patients from 20 hospitals of the Dutch
Pancreatitis Study Group, including 3 university medical
centres and 17 large teaching hospitals (see ‘Participating
Centers’ at the end of the protocol for more details).
Eligibility criteria
Patients aged 18–85 years undergoing ERCP and who pro-
vide written informed consent are included in the study.
The exclusion criteria are as follows:
– Low risk of post-ERCP pancreatitis: (1) definite
chronic pancreatitis according to MANNHEIM
criteria [15], (2) previous sphincterotomy,
(3) pancreatic head mass, and (4) routine biliary
stent exchange. In case of a pancreatic duct
intervention, chronic pancreatitis and previous
sphincterotomy are not exclusion criteria
– Acute pancreatitis
– Altered anatomy, defined as anatomical variations in
which bile and/or pancreatic secretions (in case of
pancreatic duct interventions) do not enter the
duodenum by way of the ampulla of Vater
(e.g., Roux-en-Y reconstruction, surgery for
chronic pancreatitis)
– Pregnancy
– Signs of congestive heart failure, such as pitting
edema or a New York Heart Association
classification greater than class I heart failure
– Respiratory insufficiency (pO2 < 60 mmHg or
saturation < 90% despite FiO2 of 30% or requiring
mechanical ventilation)
– Severe liver disease (cirrhosis and ascites)
– Patients receiving more than 1.5 mL/kg/h or
3 L/24 h of intravenous fluids in the 24 h before ERCP
– Hypotension (systolic blood pressure < 90 mmHg or
mean arterial pressure < 70 mmHg)
– Hypo- or hypernatremia (serum Na+ levels < 130
or > 150 mmol/L)
– Contraindications for rectal NSAIDs, including allergy,
active gastrointestinal bleeding, ulcer disease, renal
insufficiency (glomerular filtration rate < 30 mL/min)
and NSAID use for other indications (other than
cardioprotective aspirin)
Treatment arms and co-interventions
Eligibility of all potential participants will be discussed
with the central study coordinator. After written informed
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consent, patients are randomized to either the control or
intervention group. The control group will be adminis-
tered 100 mg of indomethacin or diclofenac within 30
min before or after ERCP and no hydration or mild hydra-
tion with normal saline, with a maximum of 1.5 mL/kg/h
or 3 L/24 h;. After 24 h, the volume and nature of intra-
venous infusion is at the discretion of the treating phys-
ician. The intervention group will be administered 100 mg
of indomethacin or diclofenac within 30 min before or
after ERCP and periprocedural hydration with lactated
Ringer’s solution, 20 mL/kg within 60 min from the start of
ERCP (endoscope-mouth contact), directly followed by 3
mL/kg/h for 8 h. Thereafter, the volume and nature of
intravenous infusion is at the discretion of the treating
physician.
The type, dosing, and timing of rectal NSAID applica-
tion follow the recommendations of the ESGE [4].
Current ERCP guidelines give no indication for hydra-
tion in the control group. Therefore, the hydration
schedules in both the intervention and control group are
based on the favorable results seen in Buxbaum’s pilot
study [16].
To ensure timely delivery of the 60 min bolus, pres-
sure bags or double infusion pumps will be used. The
hydration is maximized in patients with morbid obesity
(body mass index > 40), because their altered physiology
is characterized by a decrease of lean body in tissue
water content [17]. Therefore, in these patients, a max-
imum amount of fluid is calculated by using a fictive
maximum weight (FMW) associated with a body mass
index of 40 kg/m2. The FMW is calculated as follows:
FMW ¼ 40 patient length in metersð Þ2
The FMW is inserted in the fluid equations of the
intervention group.
If the clinical condition of patients in the control
group does not allow the infusion restrictions (e.g., in
Fig. 1 SPIRIT schedule of enrolment, interventions, and assessments. *Baseline variables: age, sex, comorbidity, American Society of Anesthesiologists
score, ERCP indication, PEP risk factors, use of pancreatic duct stents. ^Primary outcome: post-ERCP pancreatitis. #Secondary outcomes: incidence of
delayed PEP (> 24 h after ERCP), severity of PEP, other ERCP complications, hydration-related complications, length of hospital and intensive care unit
stay, health-related quality of life, cost-effectiveness, and exocrine and endocrine pancreatic insufficiency
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case of hypovolemic shock), higher volume infusion is
allowed at the discretion of the treating physician. Fur-
thermore, if patients in the intervention group develop
signs of fluid overload, the intensive hydration will be
stopped and, if needed, diuretics will be started.
General treatment measures include a fasting state be-
fore ERCP. Antibiotic prophylaxis, measures to correct
coagulation disorders and diet reintroduction after endo-
scopic sphincterotomy will be managed according to a
local protocol. We did not encourage the use of pancre-
atic duct stents to prevent confounding with the inten-
sive hydration regimen. After ERCP, all patients will be
hospitalized for a minimum stay of 24 h for timely diag-
nosis of adverse events and monitoring of intravenous
fluid volumes. Longer monitoring, hospitalization, and
treatment of adverse events is at the discretion of the
treating physician. Post-ERCP pancreatitis will be treated
in accordance with the International Association of Pan-
creatology/American Pancreatic Association guidelines
for treatment of acute pancreatitis [18].
To improve adherence to the trial protocol, involved
staff members (gastroenterologists, residents, physician
assistants, endoscopy nurses, ward nurses and sedation-
ists) in all participating centres will receive specific train-
ing in the trial’s standard operating procedures (SOPs). In
coordination with the local principal investigator, the
SOPs are adapted to the local hospital setting, while en-
suring adherence to the trial protocol. Furthermore, the
SOPs will be readily available on all wards and on the ded-
icated FLUYT trial website. The trial coordinator is on call
24/7 to assist in case of any questions. Protocol adherence
is evaluated regularly in participating centres.
Outcomes
The primary outcome is the incidence of post-ERCP
pancreatitis according to the Cotton criteria [19]. The
criteria of (1) new onset upper abdominal pain; (2) ele-
vation of pancreatic enzymes (amylase and/or lipase) to
more than three times the institutional upper limit of
normal; (3) criteria 1 and 2 are present at least 24 h after
ERCP; and (4) hospitalization (or extension of planned
admission) for at least 2 nights, must all be present.
The secondary endpoints (Additional file 1) are (1) in-
cidence of delayed PEP (PEP occurring > 24 h after the
procedure); (2) severity of PEP – this will be reported
according to the Cotton criteria [19] and the revised
Atlanta criteria [20] since the severity grading differs
between the two classifications [21, 22] and both are re-
ported in studies; (3) ERCP-related complications ac-
cording to the Cotton criteria [19], namely bleeding,
perforation, and infection; (4) hydration-related compli-
cations, such as pulmonary edema and congestive heart
failure; (5) length of hospital and intensive care unit stay;
(6) generic health-related quality of life, measured by the
EQ-5D and SF-36 [23, 24]; (7) cost-effectiveness; and (8)
exocrine (fecal elastase-1 < 200 μg/L) and endocrine
(HbA1c > 42 mmol/L) pancreatic insufficiency.
Sample size calculation
A recent meta-analysis [25] reported an 8% PEP inci-
dence in patients receiving prophylactic rectal NSAIDs.
We believe periprocedural hydration is a useful addition
to rectal NSAIDs if it has a similar relative risk reduc-
tion of 60% [25, 26]. This minimal clinically important
difference will cause the incidence of PEP to decrease
from 8% in the control group to 3.2% in the intervention
group, with a 4.8% absolute risk reduction. With a two-
sided significance level of 5% and a power of 80%, a total
of 718 patients (359 per treatment arm) is required to
demonstrate this effect. To account for drop-out and
missing data, we increased the sample size by 15%. This
amounts to a final number of 826 patients (413 per
treatment arm).
Randomization
Patients are randomized centrally by the study coordin-
ator in a 1:1 ratio by using a web-based randomization
module. Participants were stratified by center. Within
each stratum, random block sizes of 2, 4, and 6 were
used. Due to the large sample size, age and sex are
expected to be distributed equally between the groups.
Therefore, no additional strata are used.
Blinding
Patients and treating physicians are not blinded for
treatment allocation (see Discussion). However, a
blinded adjudication committee will assess and weigh all
events (severe complications and mortality) and decide
whether the pre-specified definitions of the primary and
secondary endpoints are met. The adjudication commit-
tee consists of six gastroenterologists with extensive
ERCP experience, a radiologist and a nephrologist. On
the basis of primary source data, each member will indi-
vidually evaluate a patient’s disease course. Disagree-
ments are resolved in a plenary consensus meeting. A
final analysis will only be performed after consensus has
been reached on each individual endpoint for each indi-
vidual patient.
Data collection methods and follow-up
Clinical data are collected locally on standardized digital
case record forms (CRFs) before ERCP, directly afterwards
and in the 24 h thereafter. CRFs were created for the en-
doscopist, nursing staff, and treating physician on which
to score the occurrence of the primary and secondary
endpoints. Endoscopy and ward nurses will monitor all
intravenous fluid infusion during the first 24 h after ERCP.
After 24 h, the treating physician will assess the primary
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endpoint (abdominal pain suggestive of PEP) and blood is
drawn for measurement of serum amylase and lipase. To
ensure data quality, the central study coordinator will
check all CRFs and contact responsible staff members in
case of inconsistencies.
All patients are followed up for 180 days after
randomization. Patients are contacted by telephone after
30, 90, and 180 days by a trial nurse. The validated EQ-5D,
SF-36, and iMTA PCQ questionnaires for measuring
quality of life and indirect non-medical costs will be sent
simultaneously by (e-)mail, with a telephone reminder after
a week if there is no response [23, 24, 27]. After 1
month of non-response, another telephone reminder
will follow and a new questionnaire will be sent. In
case of hospitalization, patients will be interviewed by
a ward nurse. If patients experienced post-ERCP pan-
creatitis, pancreatic function will be assessed at 180
days post-randomization by fecal elastase and serum
HbA1c measurements.
Unblinded, independent monitors will visit participat-
ing sites yearly for source document verification of 10%
of the CRFs, including all components of the primary
endpoint. If inconsistencies are encountered, all CRFs
will be inspected.
Statistical methods
Descriptive statistics
The baseline characteristics of age, sex, comorbidity,
American Society of Anesthesiologists score, ERCP
indication, PEP risk factors according to ESGE [4], and the
use of other prophylactics (mainly pancreatic duct stents)
will be reported. Data will be presented in percentages for
categorical variables. Continuous variables will be presented
as mean with standard deviation (normal distribution) or
median with interquartile range (skewed distribution).
Primary analysis
The primary endpoint will be analyzed according to the
intention-to-treat principle with the use of Fisher’s exact
test. That is, all randomized patients will be analyzed ac-
cording to their original treatment allocation, regardless
of study protocol violations. The only patients excluded
from the analysis will be those in whom the duodenum
was not reached and the papilla was not manipulated
(e.g., in case of upper gastrointestinal stenosis, aspiration
risk, restless patients). Because these patients did not have
an ERCP, there is no risk of PEP. Comparison of the
primary endpoint will be expressed in terms of a relative
risk and 95% confidence intervals. An exploratory per-
protocol analysis will also be performed. Reasons for
protocol violations will be described. In these analyses
we will not adjust for stratification by site. A two-
tailed P value of less than 0.05 is considered to be
statistically significant.
Additional analyses
The secondary endpoints will be compared between
treatment groups by the Student’s t test, Wilcoxon rank
sum test, Pearson’s χ2 test, or Fischer exact test as
appropriate. We cannot rule out the possibility that
pancreatic duct stents are placed. If that scenario plays
out, we will perform a sensitivity analysis of the primary
endpoint in two subgroups, namely patients that only
received rectal NSAIDs and patients that received
combination therapy with pancreatic duct stents.
Furthermore, we will conduct a sensitivity log-binomial re-
gression analysis of our primary endpoint in which we ad-
just for stratification by site. Finally, the costs and effects of
both treatment strategies within the 6 months of follow-up
will be compared. Cost-effectiveness will be expressed as
costs per patient with poor outcome (severe morbidity
and/or death) and costs per quality adjusted life year up to
180 days after randomization. Healthcare costs are regis-
tered on structured CRFs. Unit prices according to the
handbook of the Dutch Health Council are used [28, 29].
Productivity costs are measured by iMTA PCQ and quality
adjusted life years by the EQ-5D questionnaire [24, 27].
The cost-effectiveness analysis will be reported separately
from the primary study manuscript.
Safety
All adverse events, regardless of a supposed connection
to the trial, will be reported to the study coordinator. In
turn, the coordinator reports adverse events to the Cen-
tral Committee on Research Involving Human Subjects
(CCMO) according to the CCMO directive (death
within 24 h, other serious adverse events within 15 days
after the sponsor has first knowledge of the event). All
serious adverse events will be followed until they have
abated or until a stable situation has been reached.
To monitor patient recruitment and safety, an inde-
pendent data safety monitoring board (DSMB) will be
appointed (see Acknowledgments for details). Plenary
DSMB meetings will be held after inclusion of 50, 150, 413
(interim analysis), and 650 patients. The DSMB has access
to the unblinded patient data and discusses all serious ad-
verse events. These events will be tabulated and a narrative
of the complete case will be provided. All deceased patients
will be evaluated by the DSMB for cause of death and
whether this is related to a study intervention. After every
meeting, the DSMB reports to the trial steering committee.
A copy is sent to the ethical committee.
A one-sided interim-analysis of the primary endpoint
will be performed when 50% of patients (n = 413) have
been randomized and discharged. Based on the raw data
of every patient, a blinded adjudication committee will
determine if the criteria for the primary endpoint are
met. The interim-analysis will be performed by a
blinded, independent statistician who will report to the
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DSMB, which has access to unblinded data. The advice
of the DSMB will be sent to both the ethics boards and the
steering committee. Finally, the steering committee decides
whether the FLUYT trial should be continued. The Peto
approach is used for beneficial effect. For harm (higher in-
cidence of the primary endpoint in the intervention group)
no stopping rule is chosen. The trial will be terminated
using an upper stopping boundary at P < 0.001.
Discussion
The FLUYT trial will answer the question of whether
combination therapy with periprocedural hydration and
rectal NSAIDs significantly lowers PEP incidence com-
pared to NSAID monotherapy. Although several RCTs
[12, 30, 31] have investigated the value of periprocedural
hydration, they have several shortcomings.
First, only two trials [30, 31] combined periprocedural
hydration with standard-of-care PEP prophylactics such as
rectal NSAIDs. Because of the solid evidence favoring rectal
NSAID use in average- to high-risk patients [4, 7] and an
accumulating evidence base for routine use in all patients
[32, 33], patients must not be withheld rectal NSAIDs.
Second, the trials had small sample sizes ranging from 26
to 510 patients, increasing the chances of type I and II er-
rors and resulting in a power that is too low to reliably in-
vestigate an infrequent complication like PEP. This could
explain some unexpected findings that are not in line with
the current literature; for instance, two RCTs found no sig-
nificant difference between placebo and rectal NSAID
groups [30, 31]. The FLUYT trial includes 826 patients in
two parallel groups, which gives us adequate power to de-
tect a potential difference. Furthermore, our multicenter
setting allows for a higher generalizability of results.
Third, many trials deviated from the Cotton criteria to
classify PEP [19]. Instead, they defined PEP as abdominal
pain and hyperamylasemia, but these symptoms are
common after ERCP [34]. For a proper diagnosis accord-
ing to Cotton, both items should still be present 24 h
after ERCP and hospitalization should be prolonged for
at least 2 nights. The use of a less stringent PEP defin-
ition might result in an overestimation of PEP incidence.
In the FLUYT trial, we strictly adhere to the Cotton cri-
teria and all patients are hospitalized for 24 h. Not only
does this ensure timely recognition and treatment of ad-
verse events, it also allows for a precise assessment of
the primary endpoint by physical examination and meas-
urement of amylase and/or lipase 24 h after ERCP.
The design of the two trials that did use combination
therapy do not allow conclusions regarding periprocedural
hydration. One trial [30] used a four-arm parallel group de-
sign in which all trial arms received 1 L over 30 min prior
to ERCP. There was no control group without hydration
and, therefore, the additive value of hydration cannot be
assessed. The other trial [31] used a conservative hydration
schedule of 1 L over 2 h before ERCP and 2 L over 16 h
thereafter. This could explain the absence of a significant
difference in PEP incidence between the hydration and
control groups. The study group design in the FLUYT trial
allows a proper evaluation of periprocedural hydration.
With respect to fluid type, there is evidence suggesting that
lactated Ringer’s solution is preferable in the treatment of
acute pancreatitis [18]. Therefore, we chose to compare
lactated Ringer’s to a control of normal saline. With respect
to fluid volume, the vigorous hydration in our intervention
group is expected to result in a significant fluid difference
of 1.4 L directly after ERCP and 2.3 L after 9 h (for a 75 kg
patient undergoing a 1 h ERCP).
A potential drawback of the FLUYT trial design is the
lack of blinding. However, we presume that the large differ-
ence in fluid administration will lead to a notable difference
in a patient’s urine output. Furthermore, we performed a
pilot in which treating staff were blinded for treatment
allocation. It was concluded that the blinding procedure
would be both unfeasible (with respect to the multicenter
setting) and undesirable (with respect to breaking the
blinding in case of hydration-related complications).
Therefore, a blinded adjudication committee will assess the
occurrence of all primary and secondary endpoints.
The 9 h hydration schedule used in most trials raised
concerns about its cost-effectiveness. For many hospi-
tals, the schedule could prove difficult to adopt in an
outpatient ERCP practice [35]. To address this issue, we
will perform a separate cost-effectiveness analysis if our
trial finds a significant reduction in PEP incidence in the
hydration group.
Several choices in the FLUYT trial design, including
hydration schedule, fluid type, and sample size,
maximize the power of finding a difference in post-
ERCP pancreatitis if such a difference really exists.
Therefore, we can answer the question of whether peri-
procedural hydration provides additional protection
against PEP on top of rectal NSAIDs and whether this
approach is cost-effective.
Trial status
The first patient was randomized on June 5, 2015. To
date, 515 patients have been randomized and inclu-
sion rate is on schedule. Protocol version 3 is being
used and patient recruitment is expected to last until
the end of 2019.
Additional file
Additional file 1: Definitions of secondary endpoints. Table S1. Severity
of PEP according to Cotton and revised Atlanta criteria. Table S2. Local and
systemic complications according to (revised) Atlanta criteria. Table S3.
ERCP-related complications (adopted from Cotton). SPIRIT checklist.
(DOCX 40 kb)
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– P. Fockens, MD PhD, Department of Gastroenterology, Academic
Medical Centre, Amsterdam
– B.J. Witteman, MD PhD, Department of Gastroenterology, Gelderse
Vallei Hospital, Ede
– A.C. Poen, MD PhD, Department of Gastroenterology, Isala Clinics, Zwolle
– R.C. Verdonk, MD PhD, Department of Gastroenterology, St. Antonius
Hospital, Nieuwegein
– T. Bollen, MD, Department of Radiology, St. Antonius Hospital, Nieuwegein
– F. Visser, MD PhD, Department of Nephrology, Ziekenhuisgroep
Twente, Almelo
Data safety monitoring board
– R. Loffeld, MD PhD, Department of Gastroenterology and Hepatology,
Zaans Medical Centre, Zaandam (chair)
– D. Burger, MD PhD, Department of Pharmacology, Radboud University
Medical Centre, Nijmegen
– T. Nijenhuis, MD PhD, Department of Nephrology, Radboud University
Medical Centre, Nijmegen
– M. Vaneker, MD PhD, Department of Anaesthesiology, Radboud
University Medical Centre, Nijmegen
Participating centers and principal investigators
1. Albert Schweitzer Hospital, Dordrecht, The Netherlands; W. van de
Vrie, MD PhD, Department of Gastroenterology
2. Amphia Hospital, Breda, The Netherlands; T. Seerden, MD PhD,
Department of Gastroenterology
3. Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands; A. Tan, MD
PhD, Department of Gastroenterology
4. Diakonessenhuis, Utrecht, The Netherlands; A. Voorburg, MD PhD,
Department of Gastroenterology
5. Erasmus MC University Medical Centre, Rotterdam, The Netherlands; J.W.
Poley, MD PhD & M. Bruno, MD PhD, Department of Gastroenterology
6. Gelderse Vallei Hospital, Ede, The Netherlands; B. Witteman, MD PhD,
Department of Gastroenterology
7. Haga Hospital, Den Haag, The Netherlands; A. Bhalla, MD, Department
of Gastroenterology
8. Isala Hospital, Zwolle, The Netherlands; A. Poen, MD PhD, Department
of Gastroenterology
9. Jeroen Bosch Hospital, Den Bosch, The Netherlands; T. Römkens, MD
PhD, Department of Gastroenterology
10. Maasstad Hospital, Rotterdam, The Netherlands; M. Hadithi, MD PhD,
Department of Gastroenterology
11. Martini Hospital, Groningen, The Netherlands; W. Thijs, MD PhD,
Department of Gastroenterology
12. Meander Medical Centre, Amersfoort, The Netherlands; T. Schwartz,
MD PhD, Department of Gastroenterology
13. Medisch Spectrum Twente, Enschede, The Netherlands; N.G.
Venneman, MD PhD, Department of Gastroenterology
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14. Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands; L. Baak,
MD PhD, Department of Gastroenterology
15. Radboud University Medical Centre, Nijmegen, The Netherlands; E. van
Geenen, MD PhD & J. Drenth, MD PhD, Department of
Gastroenterology
16. Rijnstate Hospital, Arnhem, The Netherlands; J. Vrolijk, MD PhD,
Department of Gastroenterology
17. Spaarne Gasthuis, Haarlem, The Netherlands; R. van der Hulst, MD PhD,
Department of Gastroenterology
18. St. Antonius Hospital, Nieuwegein, The Netherlands; R. Timmer, MD
PhD & R. Verdonk, MD PhD, Department of Gastroenterology
19. VU Medical Centre, Amsterdam, The Netherlands; F. van Delft, MD &
C.J. Mulder, MD PhD, Department of Gastroenterology
20. Zuyderland Hospital, Heerlen/Sittard, The Netherlands; Y. Keulemans,
MD PhD, Department of Gastroenterology
Independent experts
– D. de Jong, MD PhD, gastroenterologist at Radboud University Medical
Centre, Nijmegen, The Netherlands (for all participating centres other
than Radboud University Medical Centre)
– Al-Toma, MD PhD, gastroenterologist at St. Antonius hospital,
Nieuwegein, The Netherlands (for the Radboud University
Medical Centre)
Key staff
– Principal investigators: E.J.M. van Geenen, MD PhD & J.P.H. Drenth,
MD PhD, Department of Gastroenterology, Radboud University Medical
Centre, Nijmegen, The Netherlands
– Coordinating investigator: X.J.N.M. Smeets, MD, Department of
Gastroenterology, Radboud University Medical Centre, Nijmegen,
The Netherlands
Ethics approval and consent to participate
The FLUYT trial will be performed in accordance with the declaration of
Helsinki and the Dutch Medical Research Involving Human Subjects Act
(WMO). Informed consent will be obtained from each patient before
inclusion in the trial. The medical ethics committee of the St. Antonius
Hospital in the Netherlands (Medical Research Ethics Committees United;
MEC-U; code 100) approved the study protocol on the 14th of April 2015
(registration number R15.008). As the FLUYT trial investigates a medicinal
product, the competent authority (Central Committee on Research Involving
Human Subjects; CCMO; code 000) carried out a marginal assessment and
approved the study on May 6, 2015. Finally, local board approval will be
obtained in all participating centres before patients are included.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Gastroenterology and Hepatology, Radboud University
Medical Centre, PO 9101, 6500 HB Nijmegen, The Netherlands. 2Department
of Radiology, St Antonius Hospital, PO 2500, 3430 EM Nieuwegein, The
Netherlands. 3Department of Gastroenterology and Hepatology, Academic
Medical Centre, PO 22660, 1100 DD Amsterdam, The Netherlands.
4Department of Gastroenterology and Hepatology, VU University Medical
Centre Amsterdam, PO Box 7057, 1007 MB Amsterdam, The Netherlands.
5Department of Gastroenterology and Hepatology, St Antonius Hospital, PO
2500, 3430 EM Nieuwegein, The Netherlands. 6Department of Health
Evidence, Radboud University Medical Centre, PO 9101, 6500 HB Nijmegen,
The Netherlands. 7Radboud Institute for Health Sciences, IQ Healthcare,
Radboud University Medical Centre, PO 9101, 6500 HB Nijmegen, The
Netherlands. 8Department of Gastroenterology and Hepatology, Erasmus
Medical Centre, PO 2040, 3000 CA Rotterdam, The Netherlands. 9Department
of Surgery, Academic Medical Centre, PO 22660, 1100 DD Amsterdam, The
Netherlands. 10Department of Gastroenterology and Hepatology, University
Medical Centre Utrecht, PO 85500, 3508 GA Utrecht, The Netherlands.
11Department of Gastroenterology and Hepatology, Spaarne Gasthuis, PO
417, 2000 AK Haarlem, The Netherlands. 12Department of Gastroenterology
and Hepatology, Isala Klinieken, PO 10400, 8000 GK Zwolle, The Netherlands.
13Department of Gastroenterology and Hepatology, Noord-West Hospital, PO
501, 1800 AM Alkmaar, The Netherlands. 14Department of Gastroenterology
and Hepatology, Medisch Spectrum Twente, PO 50000, 7500 KA Enschede,
The Netherlands. 15Department of Gastroenterology and Hepatology, Onze
Lieve Vrouwe Gasthuis, Postbus 95500, 1090 HM Amsterdam, The
Netherlands. 16Department of Gastroenterology and Hepatology, Jeroen
Bosch Hospital, PO 90153, 5200 ME s’Hertogenbosch, The Netherlands.
17Department of Gastroenterology and Hepatology, Albert Schweitzer
Hospital, PO 444, 3300 AK Dordrecht, The Netherlands. 18Department of
Gastroenterology and Hepatology, Amphia Hospital, PO 90158, 4800 RK
Breda, The Netherlands. 19Department of Gastroenterology and Hepatology,
Canisius-Wilhelmina Hospital, PO 9015, 6500 GS Nijmegen, The Netherlands.
20Department of Gastroenterology and Hepatology, Diakonessenhuis, PO
80250, 3508 TG Utrecht, The Netherlands. 21Department of Gastroenterology
and Hepatology, Hospital Gelderse Vallei, PO 9025, 6710 HN Ede, The
Netherlands. 22Department of Gastroenterology and Hepatology, HAGA
Hospital, PO 40551, 2504 LN The Hague, The Netherlands. 23Department of
Gastroenterology and Hepatology, Maasstad Hospital, PO 9100, 3007 AC
Rotterdam, The Netherlands. 24Department of Gastroenterology and
Hepatology, Martini Hospital, PO 30033, 9700 RM Groningen, The
Netherlands. 25Department of Gastroenterology and Hepatology, Meander
Medical Centre, PO 1502, 3800 BM Amersfoort, The Netherlands.
26Department of Gastroenterology and Hepatology, Rijnstate Hospital, PO
9555, 6800 TA Arnhem, The Netherlands. 27Department of Gastroenterology
and Hepatology, Zuyderland, PO 5500, 6130 MB Sittard-Geleen, The
Netherlands. 28Department of Surgery, Radboud University Medical Centre,
PO 9101, 6500 HB Nijmegen, The Netherlands.
Received: 2 January 2018 Accepted: 6 March 2018
References
1. Andriulli A, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, et al.
Incidence rates of post-ERCP complications: a systematic survey of
prospective studies. Am J Gastroenterol. 2007;102:1781–8.
2. Kochar B, Akshintala VS, Afghani E, Elmunzer BJ, Kim KJ, Lennon AM, et al.
Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic
review by using randomized, controlled trials. Gastrointest Endosc.
2015;81:143–9.
3. Elmunzer BJ. Preventing postendoscopic retrograde
cholangiopancreatography pancreatitis. Gastrointest Endosc Clin N Am.
2015;25:725–36.
4. Dumonceau JM, Andriulli A, Elmunzer BJ, Mariani A, Meister T, Deviere J,
et al. Prophylaxis of post-ERCP pancreatitis: European Society of
Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Endoscopy. 2014;46:799–815.
5. Sethi S, Sethi N, Wadhwa V, Garud S, Brown A. A meta-analysis on the role
of rectal diclofenac and indomethacin in the prevention of post-endoscopic
retrograde cholangiopancreatography pancreatitis. Pancreas. 2014;43:190–7.
6. Fan JH, Qian JB, Wang YM, Shi RH, Zhao CJ. Updated meta-analysis of
pancreatic stent placement in preventing post-endoscopic retrograde
cholangiopancreatography pancreatitis. World J Gastroenterol.
2015;21:7577–83.
7. Chandrasekhara V, Khashab MA, Muthusamy VR, Acosta RD, Agrawal D, et al.
Adverse events associated with ERCP. Gastrointest Endosc. 2017;85:32–47.
8. Cuthbertson CM, Christophi C. Disturbances of the microcirculation in acute
pancreatitis. Br J Surg. 2006;93:518–30.
9. Coté GA, Sagi SV, Schmidt SE, Lehman GA, McHenry L, Fogel E, et al. Early
measures of hemoconcentration and inflammation are predictive of
prolonged hospitalization from post- endoscopic retrograde
cholangiopancreatography pancreatitis. Pancreas. 2013;42:850–4.
Smeets et al. Trials  (2018) 19:207 Page 8 of 9
10. Kushner T, Majd N, Sigel K, Liverant ML, Wong S-Y, Patel KK, et al. Blood
urea nitrogen as a predictor of development of post-endoscopic retrograde
cholangiopancreatography pancreatitis: a case-control study. Gastrointest
Endosc. 2012;75:AB141–2.
11. Sagi SV, Schmidt S, Fogel E, Lehman GA, McHenry L, Sherman S, et al.
Association of greater intravenous volume infusion with shorter
hospitalization for patients with post-ERCP pancreatitis. J Gastroenterol
Hepatol. 2014;29:1316–20.
12. Zhang ZF, Duan ZJ, Wang LX, Zhao G, Deng WG. Aggressive hydration with
lactated ringer solution in prevention of postendoscopic retrograde
cholangiopancreatography pancreatitis: a meta-analysis of randomized
controlled trials. J Clin Gastroenterol. 2017;51:17–26.
13. Smeets XJNM, Drenth JPH, van Geenen EJM. Aggressive hydration for the
prevention of post-ERCP pancreatitis: effective when combined with rectal
NSAIDs? J Clin Gastroenterol. 2017; https://doi.org/10.1097/MCG.
0000000000000831.
14. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al.
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical
trials. BMJ. 2013;346:e7586.
15. Schneider A, Löhr JM, Singer MV. The M-ANNHEIM classification of chronic
pancreatitis: introduction of a unifying classification system based on a
review of previous classifications of the disease. J Gastroenterol.
2007;42:101–19.
16. Buxbaum J, Yan A, Yeh K, Lane C, Nguyen N, Laine L. Aggressive hydration
with lactated Ringer’s solution reduces pancreatitis after endoscopic
retrograde cholangiopancreatography. Clin Gastroenterol Hepatol.
2014;12:303–7.
17. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the
pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49:71–87.
18. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based
guidelines for the management of acute pancreatitis. Pancreatology.
2013;13(4 Suppl 2):e1–15.
19. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al.
Endoscopic sphincterotomy complications and their management: an
attempt at consensus. Gastrointest Endosc. 1991;37:383–93.
20. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al.
Classification of acute pancreatitis–2012: revision of the Atlanta classification
and definitions by international consensus. Gut. 2013;62(1):102–11.
21. Artifon ELA, Chu A, Freeman M, Sakai P, Usmani A, Kumar A. A comparison
of the consensus and clinical definitions of pancreatitis with a proposal to
redefine post-endoscopic retrograde cholangiopancreatography
pancreatitis. Pancreas. 2010;39:530–5.
22. Testoni PA, Bagnolo F, Natale C, Primignani M. Incidence of post-endoscopic
retrograde-cholangiopancreatography/sphincterotomy pancreatitis depends
upon definition criteria. Dig Liver Dis. 2000;32:412–8.
23. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36).
I. Conceptual framework and item selection. Med Care. 1992;30:473–83.
24. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72.
25. Ding X, Chen M, Huang S, Zhang S, Zou X. Nonsteroidal anti-inflammatory
drugs for prevention of post-ERCP pancreatitis: a meta-analysis. Gastrointest
Endosc. 2012;76:1152–9.
26. Akbar A, Abu Dayyeh BK, Baron TH, Wang Z, Altayar O, Murad MH. Rectal
nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents
in preventing pancreatitis after endoscopic retrograde
cholangiopancreatography: a network meta-analysis. Clin Gastroenterol
Hepatol. 2013;11:778–83.
27. Bouwmans C, Krol M, Severens H, Koopmanschap M, Brouwer W,
Hakkaart-van RL. The iMTA productivity cost questionnaire: a standardized
instrument for measuring and valuing health-related productivity losses.
Value Health. 2015;18:753–8.
28. Oostenbrink JB, Buijs-Van der Woude T, van Agthoven M, Koopmanschap MA,
FFH R. Unit costs of inpatient hospital days. PharmacoEconomics.
2003;21:263–71.
29. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Standardisation of costs:
the Dutch Manual for Costing in economic evaluations.
PharmacoEconomics. 2002;20:443–54.
30. Mok SRS, Ho HC, Shah P, Patel M, Gaughan JP, Elfant AB. Lactated Ringer’s
solution in combination with rectal indomethacin for prevention of post-ERCP
pancreatitis and readmission: a prospective randomized, double-blinded,
placebo-controlled trial. Gastrointest Endosc. 2017;85(5):1005–13.
31. Hosseini M, Shalchiantabrizi P, Yektaroudy K, Dadgarmoghaddam M,
Salari M. Prophylactic effect of rectal indomethacin administration, with and
without intravenous hydration, on development of endoscopic retrograde
cholangiopancreatography pancreatitis episodes: a randomized clinical trial.
Arch Iran Med. 2016;19:538–43.
32. Luo H, Zhao L, Leung J, Zhang R, Liu Z, Wang X, et al. Routine pre-procedural
rectal indometacin versus selective post-procedural rectal indometacin to
prevent pancreatitis in patients undergoing endoscopic retrograde
cholangiopancreatography: a multicenter, single-blinded, randomised
controlled trial. Lancet. 2016;387:2293–301.
33. Thiruvengadam NR, Forde KA, Ma GK, Ahmad N, Chandrasekhara V, Ginsberg GG,
et al. Rectal indomethacin reduces pancreatitis in high- and low-risk patients
undergoing endoscopic retrograde cholangiopancreatography. Gastroenterology.
2016;151:288–97.
34. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a
comprehensive review. Gastrointest Endosc. 2004;59:845–64.
35. Phillips AE, Papachristou GI, Slivka A. Consideration of clinical context and
alternative therapies in aggressive resuscitation for prevention of post-ERCP
pancreatitis. J Clin Gastroenterol. 2017; https://doi.org/10.1097/MCG.
0000000000000875.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Smeets et al. Trials  (2018) 19:207 Page 9 of 9
